Photocure ASA (OSL:PHO)

Market Cap	1.29B -23.0%
Revenue (ttm)	678.72M +29.8%
Net Income	78.74M
EPS	2.94
Shares Out	26.92M
PE Ratio	16.38
Forward PE	25.56
Dividend	n/a
Ex-Dividend Date	n/a

Volume	347,312
Open	48.25
Previous Close	51.70
Day's Range	46.25 - 49.00
52-Week Range	47.20 - 79.80
Beta	0.34
Analysts	Strong Buy
Price Target	82.33 (+71.16%)
Earnings Date	Jul 29, 2026

About Photocure ASA

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination product candidate for the non-surgical treatment of high-grade cervical dysplasia. The company has a license agreement with Asieris MediTech Co to develop...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 101
• Stock Exchange: Oslo Børs
• Ticker Symbol: PHO

Financial Performance

In 2025, Photocure ASA's revenue was 532.58 million, an increase of 1.37% compared to the previous year's 525.39 million. Losses were -1.52 million, -54.58% less than in 2024.

Analyst Summary

According to 3 analysts, the average rating for PHO stock is "Strong Buy." The 12-month stock price target is kr 82.33, which is an increase of 71.16% from the latest price.

Price Target

kr 82.33

(71.16% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 4, 2026

Data Sources Report a data error